Application of CAFs cell lymphatic vessel generation promotion in head and neck tumor diagnosis and treatment

Through the target of CAFs cells, dihydroartemisinin inhibits the STAT3 pathway, the role of CAFs in lymphangiogenesis in hypopharyngeal carcinoma was studied, and the problem of the unclear lymphangiogenesis mechanism in the existing technology was solved, and new The therapeutic targets of the disease have improved the diagnosis and treatment effect of hypopharyngeal carcinoma.

CN119033765APending Publication Date: 2024-11-29THE 980TH HOSPITAL OF THE CHINESE PEOPLES LIBERATION ARMY JOINT LOGISTICS SUPPORT FORCE
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411136984.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The prior art has failed to effectively clarify the relationship between lymphangiogenesis and tumor-related fibroblasts in hypopharyngeal carcinoma, and the lack of molecular mechanisms of lymphangiogenesis has affected the diagnosis and treatment of head and neck tumors.

Method used

Through CAFs cells as a target, dihydroartemisinin (DHA) is used to inhibit the lymphangiogenesis and metastasis of CAFs through the STAT3 pathway. Combined with immunohistochemical staining, cytology experiments and gene studies, we can clarify the Regulatory effects and related mechanisms.

Benefits of technology

The relationship between CAFs and lymphatic vessel density in hypopharyngeal carcinoma was clarified, and the regulatory role of CAFs in lymphatic vessel generation was clarified. It provided new targets for preventing and treating recurrence and metastasis of hypopharyngeal carcinoma, which improved diagnosis and treatment. Validity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033765A_ABST
    Figure CN119033765A_ABST
Patent Text Reader

Abstract

CAFs cell lymphatic vessel generation promotion is applied to head and neck tumor diagnosis and treatment, CAFs are taken as a target spot to inhibit lymphatic vessel generation, dihydroartemisinin is adopted, and lymphatic vessel generation promotion and metastasis of CAFs are inhibited through an STAT3 pathway, so that the CAFs cell lymphatic vessel generation promotion is applied to head and neck tumor diagnosis and treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of head and neck tumor treatment, and in particular to the application of CAFs cells in promoting lymphangiogenesis in the diagnosis and treatment of head and neck tumors. Background Art

[0002] The key and difficulty of head and neck tumor treatment lies in tumor metastasis and recurrence. Hypopharyngeal cancer is one of the subtypes of head and neck tumors, which has the characteristics of hidden onset, easy infiltration and spread, lymph node metastasis, easy recurrence, and poor prognosis. In recent years, with the increasing maturity of comprehensive treatment, hypopharyngeal cancer tends to be treated with comprehensive treatment other than surgery, but the 5-year survival rate has not improved compared with before, and the reason is the recurrence and metastasis of the tumor. Therefore, clarifying the mechanism of recurrence and metastasis of hypopharyngeal cancer is the key to developing new targeted drugs and improving prognosis.

[0003] Focusing only on tumor cells has relatively many limitations. Tumor growth requires a tumor microenvironment. Cancer-associated fibroblasts (CAFs) are key components of the tumor microenvironment and play an indispensable role in the occurrence and development of tumors. CAFs can promote tumor growth, invasion and metastasis and are associated with poor prognosis. Most CAFs are derived from the activation of normal fibroblasts, and after activation, they highly express markers such as α-smooth muscle actin (α-SMA).

[0004] Lymphangiogenesis and lymph node metastasis are important steps in tumor metastasis and are associated with poor prognosis of patients. The status of tumor lymphangiogenesis can be evaluated by tissue microlymphatic vessel density (MLVD), and lymphatic vessel endothelialhyaluronan receptor 1 (LYVE-1) is a specific marker of microlymphatic vessels.

[0005] Basic fibroblast growth factor 2 (FGF-2) is a member of the fibroblast growth factor family and plays a role in cell proliferation, migration and differentiation. FGF-2 promotes lymphangiogenesis and angiogenesis in tumors. Experimental evidence shows that FGF-2 may trigger the lymphangiogenesis switch by activating lymphatic endothelial cells.

[0006] Hypopharyngeal cancer is the subtype with the worst prognosis among head and neck tumors, and the reason is that hypopharyngeal cancer has early lymph node metastasis, distant metastasis and recurrence. Lymphatic metastasis is common in tumors, and lymphangiogenesis is a very important part of it. It is a key factor in cancer development and metastasis, and it can lead to poor prognosis. Tumors can metastasize through existing lymphatic vessels, and more often create conditions for distant dissemination by inducing lymphangiogenesis. Lymph node metastasis is an independent prognostic factor for many types of cancer. New lymphatic vessels increase the possibility that malignant tumor cells can enter the lymphatic vessels and are therefore transported to regional lymph nodes. Therefore, it is crucial to establish effective biomarkers, therapeutic targets and molecular mechanisms related to lymphatic metastasis and lymphangiogenesis.

[0007] The defects and problems of existing technologies are:

[0008] 1. The relationship between lymphangiogenesis and tumor-associated fibroblasts in hypopharyngeal carcinoma is still unclear, and the relationship between lymphangiogenesis and clinical pathological characteristics has not been reported.

[0009] 2. Tumor-associated fibroblasts are the most important cells in the tumor microenvironment, and the role of molecules in lymphangiogenesis remains to be studied. Summary of the invention

[0010] In order to overcome the above technical problems, the purpose of the present invention is to provide CAFs cells to promote lymphangiogenesis for use in the diagnosis and treatment of head and neck tumors, the regulatory role of CAFs in tumor-promoting lymphangiogenesis and related mechanisms, and dihydroartemisinin (DHA) inhibits CAFs' lymphangiogenesis and metastasis through the STAT3 pathway, thereby being used for the diagnosis and treatment of head and neck tumors.

[0011] The technical solution adopted by the present invention is:

[0012] CAFs cells promote lymphangiogenesis and are used in the diagnosis and treatment of head and neck tumors.

[0013] CAFs are used as targets for transplant lymphangiogenesis, and dihydroartemisinin (DHA) is used to inhibit CAFs' lymphangiogenesis and metastasis through the STAT3 pathway, thereby being used for the diagnosis and treatment of head and neck tumors.

[0014] CAFs promote lymphangiogenesis by secreting FGF-2.

[0015] FGF-2 inhibits the downstream STAT3 factor of FGF-2, thereby inhibiting the promoting effect of FGF-2 on lymphangiogenesis in hypopharyngeal cancer.

[0016] The regulatory role and related mechanisms of CAFs in tumor-induced lymphangiogenesis, and the feasibility of targeting tumor-associated fibroblasts for the prevention and treatment of recurrence and metastasis of hypopharyngeal cancer.

[0017] The dihydroartemisinin (DHA) inhibits the lymphangiogenesis and metastasis of CAFs through the STAT3 pathway, comprising the following steps;

[0018] First, paraffin blocks of patients were collected for immunohistochemical staining, and then statistical analysis was performed to obtain the relationship between tumor CAFs and MLVD in hypopharyngeal squamous cell carcinoma tissues and clinical pathological characteristics and prognosis;

[0019] Secondly, various cytological experiments were used to prove the role of hypopharyngeal carcinoma CAFs in promoting lymphangiogenesis through secretion of FGF-2.

[0020] Finally, the mechanism of FGF-2 promoting lymphangiogenesis was supplemented.

[0021] FGF-2 is secreted by CAFs to produce lymphangiogenesis in hypopharyngeal carcinoma. It inhibits the downstream STAT3 factor of FGF-2, thereby inhibiting the promoting effect of FGF-2 on lymphangiogenesis in hypopharyngeal carcinoma.

[0022] The regulatory role and related mechanisms of CAFs in tumor-induced lymphangiogenesis, and the feasibility of targeting tumor-associated fibroblasts for the prevention and treatment of recurrence and metastasis of hypopharyngeal cancer.

[0023] Beneficial effects of the present invention:

[0024] 1. To investigate the distribution of CAFs and MLVD in hypopharyngeal squamous cell carcinoma (HPSCC) tumor tissues, to clarify the relationship between tumor-associated fibroblasts and microlymphatic vessel density in HPSCC, and to further analyze the relationship between CAFs and tumor lymphangiogenesis and clinical pathological characteristics.

[0025] 2. At the cellular level, study and elucidate the regulatory role of HPSCC CAFs in tumor lymphangiogenesis.

[0026] 3. The present invention uses a microtubule formation experiment to visually confirm the lymphangiogenic effect of CAFs conditioned medium.

[0027] 4. This lymphangiogenesis-promoting effect is due to the growth factor secreted by CAFs. The components of this growth factor can be obtained by using ELISA to detect the components in the culture medium and tumor tissue respectively. The results showed that HPSCC tissue secreted more FGF-2 than normal tissue. Immunofluorescence staining in tumor tissue showed that FGF-2 was more expressed in the tumor stroma. Then a series of studies were conducted on FGF-2 in CAFs and NFs in different dimensions. ELISA was used from the perspective of exocrine concentration, RTPCR was used from the perspective of mRNA quantification, immunofluorescence was used to locate the expression position and expression intensity of FGF-2, and Western blot was used to quantitatively analyze the expression of FGF-2 protein. FGF-2 in CAFs is higher than that in NFs, and plays an important role in promoting the formation of new lymphangiogenesis in tumors.

[0028] 5. The present invention confirms the secretion of FGF-2 by CAFs at multiple dimensions, including gene level, intracellular protein expression level, and extracellular secretion level.

[0029] 6. The FGF-2 recombinant protein and STAT3 inhibitor DHA were applied to hLECs, and the changes in target proteins after the action were observed. According to the experimental results, it was proved that FGF-2 can lead to the activation of STAT3 in hLECs cells, causing the increased expression of VEGFR-3, thereby leading to the increase of lymphatic endothelial cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 Schematic diagram of the optimal cutoff value for analyzing α-SMA and LYVE-1 immunoreactivity using X-tile software to distinguish high / low expression groups of CAFs in HPSCC tissues.

[0031] Figure 2 Schematic diagram of the expression of α-SMA and MVLD in HPSCC tumor tissues and normal adjacent cancer tissues.

[0032] Figure 3 Schematic diagram of the correlation analysis between the expression of CAFs and MVLD in HPSCC tumor tissues.

[0033] Figure 4 Schematic diagram of Kaplan-Meier survival curve analysis of the relationship between CAFs, MLVD and survival rate in HPSCC patients.

[0034] Figure 5 Schematic diagram of the lymphangiogenesis experiment of CAFs and NFs.

[0035] Figure 6 Schematic diagram of the statistical bar graph of lymphangiogenesis after the action of CAFs and NFs.

[0036] Figure 7Schematic diagram of ELISA detection of FGF-2 concentration in HPSCC tissues and normal adjacent cancer tissues.

[0037] Figure 8 Schematic diagram of ELISA measurement of FGF-2 concentration in the conditioned culture medium of CAF1, NF1, CAF2, NF2, CAF3, and NF3.

[0038] Fig. 9 Schematic diagram of real-time fluorescence quantitative PCR comparison of FGF-2 gene expression in CAFs and NFs.

[0039] Fig.10 Schematic diagram of the immunofluorescence expression and relative intensity comparison of α-SMA and FGF-2 in CAFs and NFs cells.

[0040] Fig.11 Schematic diagram of Western blot detection of protein expression levels of α-SMA and FGF-2 in CAFs and NFs cells.

[0041] Fig.12 Schematic diagram of CCK8 detection of cell activity analysis of hLECs with different concentration gradients of DHA and DMSO.

[0042] Fig.13 Schematic diagram of the cellular changes of hLECs after the action of different concentrations of DHA.

[0043] Fig.14 Schematic diagram of the effect of FGF-2 recombinant protein with or without DHA on hLECs cells.

[0044] Fig.15 Schematic diagram of the effect of FGF-2 recombinant protein with or without DHA on the tube formation of hLECs.

[0045] Fig.16 This is a schematic diagram of the immunofluorescence expression of p-STAT3 and VEGFR-3 in human lymphatic endothelial cells hLECs after the action of FGF-2 recombinant protein and DHA.

[0046] Fig.17 This is a schematic diagram of Western blot detection of the protein expression levels of STAT3, p-STAT3, and VEGFR-3 in lymphatic endothelial cells after DHA and FGF-2 recombinant proteins acted on the cells.

[0047] Fig.18 Schematic diagram of the interaction between tumor cells, tumor-associated fibroblasts and lymphocytes in hypopharyngeal cancer tumor tissue, and the mechanism by which CAFs promote lymphangiogenesis. DETAILED DESCRIPTION

[0048] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0049] Example:

[0050] 1. Collect the patient's clinical case data and tumor / normal adjacent tissue wax block specimens;

[0051] 1.1 Collection of clinical case data of patients;

[0052] The clinical pathological data of the patients were collected according to the inclusion and exclusion criteria.

[0053] The inclusion criteria are:

[0054] a. The patient has not received any treatment before surgery, including chemotherapy, radiotherapy, targeted therapy and other adjuvant treatments;

[0055] b. Both preoperative and postoperative pathological types were diagnosed as HPSCC.

[0056] c. Exclude cases with malignant tumors in other parts of the body, cases with recurrent hypopharyngeal cancer and other cases that may affect the results of this study.

[0057] Exclusion criteria:

[0058] a. The final pathological diagnosis is not squamous cell carcinoma;

[0059] b. Other anti-cancer treatments such as radiotherapy, chemotherapy, and immunotherapy before surgery;

[0060] c. Patients with underlying diseases such as diabetes, hypertension, coronary heart disease, or with or without a history of long-term medication;

[0061] d. The paraffin-embedded lesion tissue, and the number of tumor cells in the tissue after fixation is less than 250;

[0062] e. Patients with incomplete clinical pathology and follow-up data.

[0063] Clinical case data included general clinical data, pathological data and follow-up data.

[0064] First, general clinical data included: case number, date of birth, age, sex, side, disease duration, smoking and drinking history, operation time, primary tumor site and tumor stage (including TNM stage and clinical stage), postoperative radiotherapy, postoperative complications, etc.;

[0065] Second, pathological data included: pathological grade, tumor invasion depth, vascular invasion, neural invasion, lymph node metastasis, and presence of intravascular tumor thrombus;

[0066] Third, follow-up data included: postoperative recurrence, postoperative survival time, death time and cause of death.

[0067] According to the inclusion and exclusion criteria, patients who visited the Department of Otolaryngology and Head and Neck Surgery of the 980th Hospital of Joint Logistics Support of the Chinese People's Liberation Army (Bai Qiu En International Peace Hospital) from January 1, 2010 to October 1, 2022 were screened, and the selected cases were sorted as follows according to the inclusion and exclusion criteria: Among the 91 HPSCC patients, 11 were female, accounting for 12.9%, and 80 were male, accounting for 87.9%; aged 42-81 years, with an average age of 60.4 years; follow-up time was 2-155 months, with an average of 55.6 months; 72 cases (79.1%) had tumors located in the pyriform sinus, 15 cases (16.5%) in the posterior pharyngeal wall, and 4 cases (4.4%) in the postcricoid area; 5 cases were grade I in tumor pathology, 66 cases were grade II, and 20 cases were grade III.

[0068] The TNM staging of HPSCC was determined according to the 8th edition of the American Joint Committee on Cancer (AJCC) TNM staging criteria. The N stage was determined according to the patient's postoperative lymph node pathology report. There were 5 cases (5.5%) in T1 stage, 17 cases (18.7%) in T2 stage, 22 cases (24.2%) in T1-2 stage, 32 cases (35.1%) in T3 stage, 37 cases (40.7%) in T4 stage, 69 cases (75.8%) in T3-4 stage, 25 cases (27.5%) in N0 stage, and 66 cases (72.5%) in N1-3 stage.

[0069] According to the 2018 staging standards of the Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of head and neck tumors, T1-2N0 stage was classified as early-stage patients, totaling 10 cases (11%), and T1-2N+ and T3-4 any N stage were classified as late-stage patients, totaling 81 cases (89%).

[0070] The surgical principle for hypopharyngeal cancer is to determine the surgical method and neck dissection according to the primary site and clinical TNM stage. Reduce the survival time affected by the surgical reasons. The interval from the date of surgery to the date of death or the last follow-up date is the survival time.

[0071] 1.2 Collection of tumor and normal adjacent tissue specimens;

[0072] According to the selected cases, the postoperative paraffin blocks of the patients were searched in the specimen library of the pathology department. The results of HE staining were observed to determine the tumor paraffin blocks and normal paracancerous tissue paraffin blocks. This experiment was reviewed by the hospital ethics committee with the ethics approval number (2023-KY-181). The selection criteria and exclusion criteria for pathological paraffin blocks were the same as above.

[0073] 2. Immunohistochemical staining was used to detect the expression of α-SMA and LYVE-1 proteins;

[0074] 1) Sectioning: The tumor and normal adjacent tissue specimens were sliced ​​into 3 μm sections using a microtome, adhered to an adhesive slide, bleached and dried in a 60-65°C pathology tissue bleaching and drying apparatus for 60 minutes, and then stored in a 4°C refrigerator.

[0075] 2) Slide baking: Take out the pre-stained slides from the 4°C refrigerator and arrange them on the slide rack.

[0076] Bake the slices at 62-65℃ for 30 minutes.

[0077] 3) Dewaxing: Place the slides on the slide rack in turn and immerse them in 37℃ dewaxing agent I, dewaxing agent II and dewaxing agent III for 12 minutes each.

[0078] 4) Hydration: Place the slides on the slide rack in 100% ethanol I, 100% ethanol II,

[0079] 95% ethanol for 8 minutes each, then 90% ethanol, 80% ethanol, and 70% ethanol for 7 minutes each. Again, soak in distilled water for 2 minutes, and soak in PBS buffer for 1 minute.

[0080] 5) Antigen repair: Put the antigen repair solution into the antigen repair box, put it on the steam rack, cover the box lid, put the distilled water in the pressure cooker to cover the steam rack, heat until the air is released, and put it in a ventilated place to cool after the air is released. Then place the slide in the antigen repair solution, replace the lid and the pressure cooker lid. Turn on the fire until the exhaust valve turns, count for 3 minutes, turn off the fire, and cool manually (blowing for 28 minutes, then place it in a cold water basin for 2 minutes, the water temperature in the box is about 37°C), and soak the slide in PBS buffer at 37°C for 2 minutes.

[0081] 6) Fire extinguishing: Shake the slide dry, place in a wet box, add reagent 1 (endogenous peroxidase blocker H2O2 / 1 drop), place in a 37°C water bath for 15 minutes, soak in PBS buffer for 3 minutes, and repeat 3 times.

[0082] 7) Primary antibody incubation: After drying, place in a wet box, add 1 drop of primary antibody diluted with 3% BSA (about 60ul / tissue), and incubate overnight in a 4°C refrigerator. According to the instructions of the corresponding antibodies and reference to relevant literature, LYVE-1 was diluted 1:20000; α-SMA was diluted 1:100. On the second day, take out the wet box, equilibrate at room temperature for 3-5 minutes, then put it in a 37°C water bath for 30 minutes, and rinse with PBS buffer for 3 minutes, repeat 3 times.

[0083] 8) Add reaction enhancer solution: Add reagent 2 (reaction enhancer) according to the size of the tissue: add 1 drop, incubate in a 37°C water bath for 20 minutes, soak in PBS buffer for 3 minutes, and repeat 3 times.

[0084] 9) Add enhanced enzyme-labeled goat anti-rabbit IgG polymer: add 1 drop of reagent 3 (enhanced enzyme-labeled goat anti-rabbit IgG polymer), incubate in a 37°C water bath for 20 minutes, rinse with PBS buffer for 3 minutes, and repeat 3 times.

[0085] 10) Color development: Add an appropriate amount of freshly prepared DAB to the slide, and rinse with distilled water after tissue staining under a microscope for 2-8 minutes, followed by washing with running water for 30 minutes.

[0086] 11) Re-staining: The slides were sequentially immersed in hematoxylin for 20 seconds, 1% hydrochloric acid ethanol differentiation solution for 5 seconds, rinsed in tap water for 25 seconds, and blued in warm water for 39 seconds.

[0087] 12) Dehydration: The slides were sequentially immersed in 80% ethanol for 20 seconds, 90% ethanol for 20 seconds, 95% ethanol I for 2 minutes, 95% ethanol II for 2 minutes, 100% ethanol I for 3 minutes, and 100% ethanol II for 3 minutes.

[0088] 13) Transparency: Soak the slides in Transparency I for 5 minutes, Transparency II for 5 minutes, and Transparency III for 5 minutes.

[0089] 14) Sealing: Use neutral gum and cover glass to seal the slides.

[0090] 15) Slide scanning: Use the Pannoramic SCAN II pathology slide scanner of the Hebei Medical University Public Experimental Platform to scan the slides and retain the images.

[0091] 3. Analysis of immunohistochemical staining results;

[0092] Slides stained with α-SMA and LYVE-1 antibodies were viewed using Slide Viewer software, and the following staining analysis was performed using the following method. Results were determined blindly by two experienced pathologists who were unaware of the patients' clinical information. If the results differed by >10%, they were reanalyzed.

[0093] 3.1α-SMA expression and distribution of CAFs

[0094] The expression level of α-SMA was calculated by the immunoreactive score (IRS), which included the total percentage area and staining intensity of the positive lesions. This is a semi-quantitative scoring method.

[0095] Five tumor interstitial areas were randomly selected under low magnification (200×) to observe the proportion of positively stained fibroblasts to total interstitial cells. 0 points were assigned when the percentage of α-SMA-positive cells was <1%, 1 point was assigned when the percentage of positive cells was 1% to 10%, 2 points were assigned when the percentage of positive cells was 11% to 50%, 3 points were assigned when the percentage of positive cells was 51% to 80%, and 4 points were assigned when the percentage of positive cells was >80%.

[0096] Different staining intensities, negative, mild, moderate, and severe, were marked as 0, 1, 2, and 3 points, respectively.

[0097] IRS = percentage of positive cells × staining intensity of positive cells.

[0098] The IRS of α-SMA represents the expression distribution of CAFs.

[0099] 3.2 Analysis of tissue microlymphatic vessel density;

[0100] The MLVD counts of LYVE-1-positive lymphatic vessels were performed according to the counting standard of Schoppmann's method.

[10] First, the area with the largest number of lymphatic vessels in each specimen, i.e., the most dense area and hotspots, was determined under a low-power field of view under a microscope, and then the number of microlymphatic vessels in the stained cavity was counted under a high-power microscope (×200), with each stained structure being considered as one lymphatic vessel. The number of lymphatic vessels in three high-power fields of view was counted for each tissue, and the average was calculated as the number of tumor MLVD and microlymphatic vessel density.

[0101] According to the structure of micro-lymphatic vessels, LYVE-1 positive expression is manifested as single or clustered endothelial cells under the microscope, with brown-yellow cytoplasm, no red blood cells in the lumen, and no muscular wall. Lymphatic vessels with muscular layer and lumen morphological components are not counted as micro-lymphatic vessels. If endothelial cells are positively stained or the cell clusters are clearly distinguished from adjacent tumor cells and other interstitial components, a micro-lymphatic vessel can be counted regardless of whether there is a lumen. Among them, whether there are obvious endothelial cells or not, as long as the lumen is obvious and the wall is intact, it is counted as one micro-lymphatic vessel; if the wall is incomplete, there are endothelial cells or multiple tortuous lumens in clusters are counted as one micro-lymphatic vessel.

[0102] MLVD: The average number of LYVE-1-stained lymphatic vessels in three lymphatic “hot spots” in each section.

[0103] 3.3 Selection of the optimal cutoff value

[0104] Based on the overall survival status and survival time, we used X-tile software to determine the optimal cutoff values ​​of α-SMA and MLVD to identify the high- and low-density groups of CAFs and MLVD in HPSCC patients.

[0105] 4. Treatment of experimental cells;

[0106] 4.1 Primary culture and identification of CAFs and NFs cells (Ethics approval number: 2023-KY-181)

[0107] 1) Tissue block method: fresh pharyngeal cancer tumor tissue and adjacent normal mucosal tissue above the safe margin of the tumor that meet the inclusion criteria removed during surgery. Place the fresh tissue block in a 15ml covered centrifuge tube with D-hanks solution and bring it back to the sterile clean bench in the laboratory as soon as possible. Disinfect the mouth of the specimen tube with alcohol and place it on the clean bench tube rack. Take out the tissue and place it in a culture dish, wash it with an appropriate amount of D-hanks solution, and repeat twice. Use scissors to cut the tissue into pieces as finely as possible. Use a Pasteur pipette to aspirate a small amount of culture medium to rinse the tissue fragments on the scissors, and transfer the cut tissue into a cell culture bottle, and place it in a cell culture incubator at 37°C and 5% CO2 with saturated humidity for culture.

[0108] 2) Enzyme digestion (type II collagenase 0.1%)

[0109] Add 500μl of type II collagenase storage solution to 10ml DMEM complete medium and mix thoroughly. Add the plate with shredded tissue pieces, mix well by blowing, add to the centrifuge tube, place in a 37℃ 5% CO2 incubator for digestion for 1.5 hours, and gently shake upside down 5-6 times every 15 minutes to help enzyme digestion. Then put the centrifuge tube into a low-speed centrifuge at 1500rpm / min for 5 minutes, discard the supernatant, add 5ml of DMEM complete medium to resuspend, repeat centrifugation 2 times, inoculate in a T25 cell culture flask after resuspending, add 5ml of DMEM complete medium, shake evenly, and place in a 37℃ 5% CO2 cell culture incubator.

[0110] The experiments used primary culture cells from passage 4 to 8.

[0111] The identification of primary cells using immunofluorescence and Western blot methods has been conducted by other members of our laboratory and will not be repeated here.

[0112] 4.2 Cell recovery;

[0113] Expose the clean bench and room to ultraviolet light for 30 minutes in advance, heat the constant temperature water bath to 37°C, and add 5ml DMEM complete medium to the sterile centrifuge tube. Take out the frozen cells (CAFs, NFs, hLECs) from the liquid nitrogen tank and quickly place them in a 37°C water bath to thaw. Do not immerse the tube mouth in water. After thawing, spray alcohol and transfer to the clean bench. Remove the sealing film, wipe the cryopreservation tube mouth with alcohol cotton balls, suck the frozen cells into a 15ml centrifuge tube, blow gently to mix, and centrifuge at 1500rpm for 5 minutes in a low-speed centrifuge. Discard the supernatant, add 5ml DMEM complete medium, gently blow and resuspend the cells, then transfer them to a cell culture bottle and place them in a cell culture incubator at 37°C and 5% CO2 saturated humidity for culture.

[0114] 4.3 Cell passaging;

[0115] 1) hLECs cells: For hLECs cells in the logarithmic growth phase, discard the original culture medium, add 5ml D-Hanks solution to wash, repeat twice, add 0.25% Trypsin-EDTA and place in a cell culture incubator to digest the cells for 1 minute. Under the microscope, the cells become spherical, and DMEM complete culture medium is added to terminate the digestion. Repeatedly blow and beat to detach the cells from the wall and make them suspended. The single cell suspension is sucked into a centrifuge tube, centrifuged at 1500rpm / min for 5 minutes, and 5ml ECM complete culture medium is added to resuspend by blowing. After 1:2 or 1:3 passaging, place them back in a cell culture incubator at 37℃, 5% CO2 and saturated humidity, and change the medium once every 2 to 3 days.

[0116] 2) Hypopharynx squamous cell carcinoma CAF1, CAF2, CAF3, NF1, NF2, NF3 cells: For CAF1, CAF2, CAF3, NF1, NF2, NF3 cells in the logarithmic growth phase, discard the original culture medium, gently wash with D-Hanks solution, repeat twice, add 0.05% Trypsin-EDTA to digest the cells, put them in a cell culture incubator for digestion for 3 minutes, observe the bottom of the culture bottle with naked eyes to be ground glass-like, and the cell shape under the microscope becomes spherical, and add DMEM complete culture medium to terminate digestion. Repeatedly blow and beat to allow the cells to detach from the wall and become suspended, and the single cell suspension is sucked into a 15ml centrifuge tube, centrifuged at 1500rpm / min at a low speed for 5 minutes, and 5ml DMEM complete culture medium is added to blow and resuspend, and after 1:2 or 1:3 passaging, place them back in a cell culture incubator at 37℃ and 5% CO2 saturated humidity, and change the medium once every 2 to 3 days.

[0117] 4.4 Cell cryopreservation;

[0118] Prepare cell freezing solution by mixing FBS and DMSO in a ratio of 9:1 in advance. Take out the cells to be frozen, discard the culture medium, add D-Hanks solution to gently wash, repeat 3 times, add 0.25% / 0.05% Trypsin-EDTA to digest the cells, add 5ml DMEM complete culture medium to terminate the digestion, pipette the cells into a single cell suspension, transfer them into a centrifuge tube, centrifuge at a low speed of 1500rpm / min for 5 minutes, discard the supernatant, add the prepared freezing solution, pipette and resuspend, and then divide into cryopreservation tubes. The cryopreservation tubes are programmed to cool down, use an application cooling box, or place them in a 4℃ refrigerator for 10 minutes, place them in a 20℃ refrigerator for 30 minutes, transfer them to a -80℃ refrigerator overnight (<16h), and finally store them in liquid nitrogen.

[0119] 4.5 Preparation of cell suspension and cell counting;

[0120] Select the cells to be counted, discard the original culture medium, add 5ml sterile D-Hanks solution to wash the cells, and repeat twice. Add 1-3ml 0.05% or 0.25% Trypsin-EDTA containing EDTA to digest the cells, so that the trypsin can completely infiltrate the cells attached to the bottom of the bottle. Digest in a 37°C cell culture incubator for 3-5 minutes. Observe the frosted glass at the bottom of the bottle with the naked eye. After the cells become round under the microscope, stop digestion with 5ml DMEM complete culture medium. Repeatedly blow the bottom of the bottle to make it detach from the wall and become a single cell suspension. Clean the cell counting plate and coverslip with anhydrous ethanol or 95% ethanol, and cover the coverslip with the counting plate. Drop 10ul of cell suspension on the edge of the coverslip so that the cell suspension fills the space between the coverslip and the counting plate. Do not allow bubbles or overflow. Under a microscope, use a 10× objective to count the number of cells in the large squares on the counting plate. Only the cells on the left and above the line are counted in the result. The formula is: number of cells / ml = (total number of cells in 4 large grids / 4)×104 If cell clusters consisting of two or more cells are occasionally seen under the microscope, count them as single cells. If more than 10% of the cells are cell clusters, it means that the dispersion is not good and the cell suspension can be re-prepared.

[0121] 5. Preparation of conditioned medium;

[0122] Conditioned medium for CAF1, CAF2, CAF3, NF1, NF2, and NF3: CAF1, CAF2, CAF3, NF1, NF2, and NF3 cells with a confluency of 80% to 90% in a 100 mm cell culture dish were washed with D-Hanks solution twice, and 10 ml of DMEM medium containing double antibodies but without FBS was added. The cells were cultured for 48 hours, and the medium was collected into a centrifuge tube and centrifuged at a low speed of 1500 rpm / min for 15 minutes. After removing the cell debris, the supernatant was dispensed into 1.5 ml sterile EP tubes and marked as CM. CAF1 CM CAF2 CM CAF3 CM NF1 CM NF2 CM NF3 , and store at -80℃ for future use.

[0123] 6. In vitro three-dimensional culture tube formation test of lymphatic endothelial cells;

[0124] 1) Preparation: Put the Matrigengel from -80℃ freezer into ice box and keep it in 4℃ refrigerator overnight to make it liquid. Pre-cool the pipette tip, 96-well plate and EP tube in 4℃ refrigerator.

[0125] 2) Laying Matrigel: On the second day, take out Matrigel, pipette tip, 96-well plate, and EP tube and place them on ice. Use pre-cooled pipette tip to vertically add 50ul Matrigel into the pre-cooled 96-well plate to avoid bubbles. Place the 96-well plate flat in a 37℃ CO2 incubator and incubate for 1 hour to solidify the Matrigel.

[0126] 3) Preparation of single cell suspension: While waiting for the gel to form, take hLECs cells and gently wash them with D-Hanks solution, repeat 3 times, add 0.25% Trypsin-EDTA to digest the cells for 1 minute, add DMEM complete medium and resuspend them into single cell suspension by pipetting, and count the cell density of the single cell suspension. CAF1 CM CAF2 CM CAF3 CM NF1 CM NF2 CM NF3The final concentration of the cell suspension was 6×10 5 / ml.

[0127] 4) Inoculation of cells: Take out the 96-well plate from the incubator, add 50 μl of the prepared single cell suspension to each well vertically above the well, and repeat for 3 wells (do not touch the Matrigengel below). After incubation in a 37°C incubator for 4-8 hours, observe the arrangement of the tubular structure and the integrity of the lymphatic vessels. Take pictures under a microscope.

[0128] 7. Enzyme-linked immunosorbent assay (ELISA) was used to detect the concentration of FGF-2;

[0129] 1) Add 300 μl of washing solution to the wells to be used and soak for 30 seconds.

[0130] 2) Add 100 μl of 8 standards (2-fold dilution) to the standard wells, 100 μl of standard diluent to the blank wells, and 100 μl of cell-conditioned medium (CM) to the sample wells CAF1 CM CAF2 CM CAF3 CM NF1 CM NF2 CM NF3 ; Dilute tissue grinding solution 5 times.

[0131] 3) Add 50 μl of antibody solution (1:100 dilution) to all wells, seal the plate with a sealing film, incubate at room temperature for 2 hours, wash with washing solution, and repeat 6 times.

[0132] 4) Add 100 μl of streptavidin working solution (1:100 dilution) to all wells, seal the plate with a sealing film, incubate at room temperature for 45 minutes, wash with washing solution, and repeat 6 times.

[0133] 5) Add 100ul of chromogenic substrate to all wells, protect from light, and incubate at room temperature for 5 to 30 minutes.

[0134] 6) Add 100ul of stop solution to all wells and perform dual-wavelength detection using an ELISA reader within 30 minutes, with 450nm as the maximum absorption wavelength and 570nm as the reference wavelength, to detect the absorbance OD value.

[0135] 8. Fluorescence quantitative PCR;

[0136] 8.1 Extract total RNA (use sterile and enzyme-free pipette tips and centrifuge tubes);

[0137] 1) Use a micropipette to remove the culture medium from the culture dish, add 4°C pre-cooled PBS solution, and shake gently to wash.

[0138] 2) Discard PBS, add 1 ml of RNA extraction solution, shake gently, blow with a pipette tip to break the cells, and transfer to a 1.5 ml centrifuge tube.

[0139] 3) Add 100 μl of chloroform substitute, shake the centrifuge tube up and down for 15 seconds, mix thoroughly, let stand at room temperature for 3 minutes, and centrifuge at 4°C at 12,000 rpm for 10 minutes.

[0140] 4) Take 400 μl of the supernatant and add it to a new centrifuge tube, add 550 μl of isopropanol, mix well, and place in a -20°C refrigerator for 15 minutes.

[0141] 5) Centrifuge at 12,000 rpm for 10 minutes at 4°C. The white precipitate at the bottom of the tube is RNA. Discard the supernatant and add 1 ml of 75% ethanol. Invert and mix to wash the precipitate. Centrifuge at 12,000 rpm for 5 minutes at 4°C. Repeat the RNA precipitate washing process.

[0142] 6) Aspirate and discard the supernatant, place on a clean bench and blow for 5 minutes, then add 15 μl of RNA dissolving solution.

[0143] 7) Use Nanodrop2000 to detect RNA concentration and purity: After the instrument is blanked and zeroed, take 2.5 μl of the RNA solution to be tested on the detection base, put down the sample arm, and use the software on the computer to start absorbance detection.

[0144] 8) Dilute the RNA to a final concentration of 200 ng / μl and store in a -80°C refrigerator for later use.

[0145] 8.2 Reverse transcription;

[0146] 1) Preparation of reverse transcription reaction system

[0147]

[0148] 2) Mix gently and centrifuge.

[0149] 3) Set up the reverse transcription program and complete the reverse transcription on a common PCR instrument.

[0150]

[0151]

[0152] 8.3 Quantitative PCR;

[0153] 1) Take 0.1 ml of PCR reaction plate and prepare the following reaction system, preparing 3 tubes for each reverse transcription product.

[0154] After spotting, use PCR plate sealing film and a sealing instrument to seal the plate, and then centrifuge in a microplate centrifuge.

[0155]

[0156] 2) PCR amplification: completing the amplification on a fluorescent quantitative PCR instrument.

[0157]

[0158] 3) The primer sequences used are as follows:

[0159]

[0160] 8.4 Result processing

[0161] ΔΔCT method:

[0162] A = CT (target gene, sample to be tested) - CT (internal standard gene, sample to be tested)

[0163] B = CT (target gene, control sample) - CT (internal standard gene, control sample)

[0164] K=AB

[0165] Expression multiple = 2 -K

[0166] 9. Immunofluorescence staining of cells;

[0167] 1) Cell collection: Select CAF1, CAF2, CAF3, NF1, NF2, and NF3 cells in the logarithmic growth phase, digest the cells with 0.05% trypsin, prepare a single cell suspension, count the cell density of the single cell suspension, and dilute the cell suspension with DMEM complete medium to a concentration of 2000 cells / 1ml. Use tweezers to pick up a clean round cell slide and place it in a well of a 24-well plate. Inoculate each well with 1ml of the diluted cell suspension, and place the 24-well plate in a cell culture incubator at 37°C and 5% CO2 with saturated humidity overnight to allow the cells to adhere to the wall.

[0168] 2) Fix cells: On the second day, aspirate the medium in each well of the 24-well plate, add 1 ml of PBS, and place the 24-well plate on a horizontal shaker to rinse for 3 minutes. Repeat twice. Aspirate the PBS, add 500 ul of 4% paraformaldehyde to each well, and place at room temperature for 20 minutes. Discard the 4% paraformaldehyde, add 1 ml of PBS, and gently shake on a shaker to rinse for 3 minutes. Repeat 3 times.

[0169] 3) Punch cells: Aspirate PBS, add 500ul of 0.1% Triton X-100 to each well, and leave at room temperature for 15 minutes. Aspirate Triton X-100, add 1ml of PBS, shake gently on a shaker for 3 minutes, and repeat 3 times.

[0170] 4) Blocking: Aspirate PBS, add 500ul of 3% BSA blocking solution to each well, and place at 37°C for 40 minutes.

[0171] 5) Primary antibody incubation: Aspirate BSA, add 140 μl / well of primary antibody solution diluted with 3% BSA, and store in a 4°C refrigerator overnight in the dark. Referring to the antibody instructions and previous literature, the dilution ratio of the primary antibody solution was set as: FGF-2, 1:2400; α-SMA, 1:200.

[0172] 6) Fluorescent secondary antibody incubation: The next day, aspirate the primary antibody solution, add 1 ml of PBS, shake gently on a shaker for 3 minutes, and repeat 3 times. Aspirate the PBS, add AlexaFluor488 goat anti-rabbit IgG fluorescent secondary antibody solution diluted with 3% BSA (dilution ratio 1:400), 140 μl / well, and incubate at 37°C in the dark for 60 minutes. Discard the secondary antibody, add 1 ml of PBS, shake gently on a shaker in the dark for 3 minutes, and repeat 3 times.

[0173] 7) DAPI nuclear staining: After aspirating PBS, add 140 μl / well of DAPI solution diluted with 3% BSA (dilution ratio 1:50), and incubate at 37°C in the dark for 30 minutes. Aspirate DAPI, add 1 ml of PBS, and gently shake on a shaker in the dark for 3 minutes, and repeat 3 times.

[0174] 8) Sealing: Add 500ul of PBS to each well, gently pry up one end of the cell slide with a 5ml syringe needle, pinch the slide with flat tweezers and use filter paper to absorb the liquid on the slide, take a clean slide, add 1 drop of anti-fluorescence quenching sealing liquid, cover the cell slide with the top facing down with the sealing liquid, immerse the cell slide in the sealing liquid, and do not generate bubbles. Fix the cell slide with four points of transparent nail polish, observe the fluorescence staining under a fluorescence microscope and take pictures, and analyze the expression position and expression intensity of the target protein fluorescence.

[0175] 10. Western blot detection of protein expression

[0176] 1) Extract cell protein: The cells were inoculated in a 100mm culture dish and placed in a cell culture incubator at 37°C and 5% CO2 with saturated humidity. When the cell saturation growth reaches more than 90%, remove the culture dish, add D-Hanks solution to rinse the cells twice, discard the D-Hanks solution, and pour a little liquid nitrogen into the culture dish. Remove the culture dish from the liquid nitrogen, place it on ice, add RIPA lysis solution (1ml RIPA + 20μl phosphatase inhibitor), and lyse on ice for 10 minutes. Quickly scrape the cell lysate repeatedly in the culture dish with a cell spatula and collect it in a 1.5ml EP tube. Continue lysis on ice for 20 minutes, vortexing every 10 minutes. Place the EP tube in a 4°C low-temperature refrigerated centrifuge, centrifuge at 12000rpm / min for 20 minutes, and save the supernatant at -80°C for freezing.

[0177] 2) BCA protein quantification: dilute the standard with PBS to the following concentrations: 2mg / ml, 1mg / ml, 0.5mg / ml, 0.25mg / ml, 0.125mg / ml, 0g / ml. Take 20μl of the standard solution in each 96-well plate and add it to 6 wells in turn. Dilute the protein sample by 2 times, add 20μl to each well, and set up 2 replicate wells for each sample. According to the instructions of the protein quantification kit, add 200μl of the mixture of solution A and solution B (solution A: solution B = 50:1) to each well, shake gently on a horizontal shaker for 1 minute, place in a 37℃ incubator for reaction for 30 minutes, and use an enzyme marker to detect the OD value at a wavelength of 562nm. Draw a protein standard curve with the OD value as the horizontal axis and the standard protein mass mg as the vertical axis. Calculate the protein concentration of each extracted sample according to the formula obtained from the curve, and balance the protein samples to the same concentration with lysis buffer.

[0178] 3) Packaging and denaturation of protein samples: Add 1 / 5 volume of 5× loading buffer to all protein samples, vortex to mix, denature with a constant temperature mixer at 97°C for 10 minutes, and then store in a -80°C refrigerator for later use.

[0179] 4) Prepare PAGE gel: The glass plate (1mm thick) is neatly fixed on the gel rack, and the lower edge is tightly fitted with the gel pad to prevent gel leakage. Prepare a 10% gel according to the instructions of the gel preparation kit. After mixing 3ml of the lower gel solution and 3ml of the lower gel buffer, add 60μl of the improved coagulant, and quickly inject the solution into the glass plate for gel preparation. Leave a little solution in the gel cup to judge the gel coagulation. Fill the glass plate with anhydrous ethanol to cover the lower gel and flatten the lower gel. Wait for about 15 minutes for the lower gel to solidify, pour out the ethanol, and absorb the residual ethanol with clean filter paper. Mix 1ml of the upper gel solution, 1ml of the colored upper gel buffer, and 20μl of the improved coagulant, fill the glass plate with the solution, insert one side of the electrophoresis comb into the glass plate first and then slowly insert it into the other side, otherwise bubbles are easily generated, and solidify at room temperature for about 15 minutes.

[0180] 5) SDS-PAGE electrophoresis: Remove the gel from the gel rack, fix it on the glass plate sealing rack, put it into the electrophoresis tank, add an appropriate amount of 1×Tris-glycine electrophoresis buffer inside and outside the tank, and pull out the comb vertically with both hands with even force. Take out the protein sample and thaw it first. Use a pipette to add 35-38μl of protein sample to each well, add 3μl of standard protein Marker to the two edge loading wells as a control, fill the Marker wells and blank wells with 1× loading buffer, and add an equal amount of 1× loading buffer to the protein sample on both sides. Turn on the power of the electrophoresis instrument, and run electrophoresis at 150V at room temperature for 50 minutes, or stop the electrophoresis when the bottom line of the Marker protein runs out of the gel. Take out the glass plate from the electrophoresis tank and gently pry it open, remove the excess gel according to the molecular weight of the target protein, and soak the gel in the transfer buffer to reduce deformation.

[0181] 6) Transfer: Cut 6 pieces of filter paper of the same size as the gel in advance and put them in the transfer buffer for balance. Cut a 0.22μm PVDF membrane of the same size as 1 piece of gel, cut off the upper left corner with scissors to identify the target protein and the front and back of the membrane, and activate it in methanol for 1 minute. Make a "sandwich" in the transfer clip in order: black side of the transfer clip, sponge pad, 3 layers of filter paper, gel, PVDF membrane, 3 layers of filter paper, sponge pad, white side of the transfer clip. During operation, fit each layer tightly to prevent bubbles from affecting the transfer effect. Clamp the transfer clip and put it in the electrotransfer tank, add transfer buffer to the tank, place ice cubes inside and outside the tank to cool it down, turn on the power, and transfer the membrane at 260mA for 30 minutes-100 minutes.

[0182] 7) Blocking: After the transfer, wash the PVDF membrane with TBST once, put it in 5% BSA, and block it with a horizontal shaker for 70 minutes at room temperature. Use a ballpoint pen to mark the molecular weight of each marker, and cut the PVDF membrane according to the molecular weight of the target protein and the marker.

[0183] 8) Primary antibody hybridization: After blocking, remove the PVDF membrane, place it in an antibody incubation box, and incubate it overnight at 4°C. Refer to the antibody instructions and previous literature, dilute the primary antibody with 5% BSA, and the primary antibody dilution ratios are: α-SMA, 1:2000; FGF-2, 1:5000; β-actin, 1:15000.

[0184] 9) Secondary antibody hybridization: Take the antibody incubation box out of the refrigerator and shake slowly at room temperature for 1 hour. Wash the membrane on a shaker with 1×TBST for 10 minutes, repeat 3 times. Put the membrane into the secondary antibody diluent (HRP goat anti-rabbit IgG) (diluted 1:15000 with TBST solution), incubate on a shaker at room temperature for 1 hour. Wash the membrane with 1×TBST for 15 minutes, repeat 3 times.

[0185] 10) ECL color development and analysis: ECL chemiluminescent solution A and solution B were mixed at a ratio of 1:1, the PVDF membrane was removed, the residual liquid was drained, the membrane was placed in a GBOX gel imager, and the chemiluminescent solution was evenly added and photographed. The gray value of the target protein was analyzed using Image J software.

[0186] 11. Cell activity analysis (CCK-8 method);

[0187] 1) Inoculation of cells: hLECs cells in the logarithmic growth phase were taken, digested and made into a single cell suspension, diluted with ECM complete medium to an appropriate cell density (about 2-30,000 cells / ml), and 100 μl was inoculated into a 96-well culture plate, with 5 replicate wells in each group (the outermost culture wells of the 96-well culture plate were not inoculated with cells, and sterile PBS solution was added, 200 μl per well, to prevent liquid evaporation from affecting the experimental results), and cultured in a 37°C, 5% CO2 incubator overnight.

[0188] 2) Drug treatment: After the cells adhered, 100 μl of freshly prepared DHA working solution of different concentrations (the concentrations were set to 0, 80, 160, 320, 640 and 1280 μM) was added to the control group, and the same dose of DMSO (the concentrations were marked as 0, 80, 160, 320, 640 and 1280 μM, and the maximum dose did not exceed 0.01%) was used when diluting DHA. At the same time, blank control wells (wells with the same volume of cell culture medium, drugs but no cells were added as blank controls) were set up. Incubate in a 37°C, 5% CO2 incubator for 24 hours.

[0189] 3) Add CCK-8 solution: Take out the 96-well plate and place it in the clean bench, add 10μl CCK-8 solution to each well, gently tap to mix, and place the culture plate in a 37℃ incubator for 1 to 4 hours. Preliminary experiments recommend using an ELISA reader to detect after 2, 3, and 4 hours, and finally select a time point with a more suitable absorbance range for subsequent experiments, that is, the absorbance of the control group is about 1.2. (3 hours was selected in this experiment)

[0190] 4) On-machine detection: The wavelength of the microplate reader is set to 450 nm to measure the absorbance OD value.

[0191] 5) Calculation formula: Survival rate % = (absorbance of experimental group - absorbance of blank group) / (absorbance of control group - absorbance of blank group) %

[0192] 12. Effect of DHA on hLECs cell morphology

[0193] 1) Seeding cells: hLECs cells were seeded in a 96-well culture plate at a cell density of 2-3×10 4 / ml, the inoculation volume was 100 μl / well, and the cells were placed in a 37°C, 5% CO2 incubator and incubated overnight.

[0194] 2) DHA intervention: The 96-well plate was removed from the incubator, the culture medium was aspirated, the plate was washed twice with D-Hanks solution, and 100 μl / well of DHA working solution of different concentrations were added, with the concentrations set to 0, 40, 80, 160, 320, 640, and 1280 μM.

[0195] 3) Continue culturing for 24 h, observe the morphological changes of hLECs cells under an inverted microscope and take photos.

[0196] 13. Lymphangiogenesis Assay

[0197] 1) The process of preparing and laying matrix gel is the same as in Part 2.

[0198] 2) Preparation of single cell suspension and drug treatment: While waiting for the gel, take hLECs cells, wash gently with D-Hanks solution, repeat 3 times, add 0.25% Trypsin-EDTA to digest the cells for 1 minute, add DMEM complete medium and resuspend them into single cell suspension by pipetting, and count the cell density of the single cell suspension. The experimental groups were blank control group, DHA group, FGF-2 group, FGF-2+DHA group, and the drug and hLECs single cell suspension were mixed in a 1:1 ratio for standby use (FGF-2 concentration was 5nM, and the final DHA concentration was 80μM). The control group was mixed with hLECs single cell suspension and DMEM complete medium. The final concentration of the cell suspension was 6×10 5 / ml.

[0199] 3) Inoculation of cells: Take out the 96-well plate from the incubator, add 50 μl of the prepared single cell suspension to each well vertically above the well, and repeat for 3 wells (do not touch the Matrigel below). Incubate in a 37°C incubator, and observe the arrangement of the tubular structure and the integrity of the lymphatic vessels for 4-8 hours. Take pictures under a microscope.

[0200] result:

[0201] 1. Optimal cutoff value:

[0202] The overall survival status, survival time, and expression of target factors were input into the X-tile software to obtain the optimal cutoff values ​​of α-SMA and MLVD to determine the α-SMA high and low expression groups and MLVD high and low densities of HPSCC patients. Figure 1 .

[0203] The optimal cutoff values ​​of each factor are as follows: the optimal cutoff value of α-SMA = 4.4, and the optimal cutoff value of MLVD = 18. α-SMA and MLVD were grouped according to the cutoff values: IRS>4.4 was defined as high expression of α-SMA, and IRS≤4.4 was defined as low expression of α-SMA; MLVD>18 was defined as high density, and MLVD≤18 was defined as low density. CAFs were grouped according to the IRS score of α-SMA.

[0204] 2. Expression and distribution of α-SMA in CAFs:

[0205] According to the research results, the distribution density and intensity of α-SMA are higher than other markers when comparing multiple CAFs markers. Therefore, the IRS score of α-SMA expression is used to evaluate the expression distribution of CAFs. The distribution of α-SMA immunohistochemically positive cells in hypopharyngeal cancer tissue and adjacent normal tissue was observed. The study showed that α-SMA is expressed in the cytoplasm of fibroblasts in the tumor stroma, and is also positive in the walls of microvessels and glandular tissues. CAFs are mainly distributed in the stroma of tumor tissue, between cancer nests, and between cancer nests and normal tissues (see Figure 2 ). According to the optimal cutoff value of α-SMA, it was lowly expressed (IRS≤4.4) in 18 cases (19.8%) and highly expressed (IRS>4.4) in 80.2% (73 cases). The average IRS of CAFs in HPSCC tumor stroma was 7.92, which was significantly higher than that in adjacent normal resection tissue (P<0.001).

[0206] 3. Expression of LYVE-1 and distribution of MLVD:

[0207] LYVE-1 positive expression appears brown or yellow-brown in the cytoplasm of lymphatic endothelial cells. Regardless of the staining intensity of the positive cells, as long as the positive expression is positive, it marks a micro-lymphatic vessel (see Figure 2 The number of microlymphatic vessels in the stained cavity under high-power microscope (×200) was counted, and the average MLVD was 21.92, which was significantly higher than that of the normal resection margin tissue adjacent to the cancer (P<0.001) (see Table 1 for details).

[0208] Through LYVE-1 staining, it was observed that the lymphatic vessels in the tumor nests were squeezed and collapsed, occluded and atrophied in strips. The lumens of small micro-lymphatic vessels in the tumor stroma were visible. The lymphatic endothelial cells were mostly arranged in disorder and had various twisted shapes. Occasionally, cells were seen in the lumens. The lumens were visible in the normal adjacent tissues and were dilated.

[0209] Table 1 Distribution of CAFs and MLVD in HPSCC tumor tissues and normal tissues at the resection margin

[0210]

[0211] Note: T, tumor tissues; N, normal adjacent tissues.

[0212] 4. Correlation between CAFs and MLVD:

[0213] Spearman rank correlation analysis was performed on the expression of CAFs and the distribution of MLVD. The results showed that there was a positive correlation between CAFs and MLVD. The correlation coefficient between CAFs and MLVD was 0.261 (P = 0.012), which was statistically significant (see Figure 3 ).

[0214] Chi-square test was performed on the different distribution densities of CAFs and MLVD according to the above grouping. The results showed that there was a significant correlation between the different distribution densities of CAFs and MLVD. 2 =4.643, P=0.031) (see Table 2). This further shows that the high-density distribution of CAFs is consistent with the high-density distribution of MLVD, and the low-density distribution of CAFs is consistent with the low-density distribution of MLVD.

[0215] Table 2 Correlation between CAFs and MLVD in HPSCC tumor tissues

[0216]

[0217] Note: Low, low density; High, high density.

[0218] 5. Relationship between CAFs, MLVD and clinical pathological characteristics:

[0219] The immunohistochemical staining results of CAFs and MLVD were statistically analyzed with chi-square test for six clinical pathological characteristics, including tumor size, clinical pathological grade, T grade, N grade, invasion depth, and nerve invasion, to analyze the corresponding correlation. If the theoretical frequency was ≥5, the chi-square test was used, and if the theoretical frequency was <5, the Fisher exact probability method was used. The results showed that in 91 HPSCC cases, high expression of CAFs was significantly correlated with clinical stage and T stage (P<0.01). High expression of CAFs was closely correlated with tumor size and tumor invasion depth (P<0.05). High density of MLVD was closely correlated with clinical stage, T stage, N stage, tumor invasion depth, and nerve invasion (P<0.05). (See Table 3).

[0220] Table 3 Correlation between the distribution of CAFs and MLVD and clinicopathological characteristics in HPSCC

[0221]

[0222]

[0223] Note: L, low density; H, high density; *, Fisher's exact test.

[0224] 6. Survival Analysis:

[0225] According to the optimal cutoff value, the postoperative survival rate of patients in the high-density CAFs group was significantly lower than that in the low-density CAFs group (χ 2 =6.397,P=0.011)( Figure 4 A). The postoperative survival rate of patients in the MLVD high-density group was significantly lower than that in the low-density group (χ 2 =6.883,P=0.009)( Figure 4 B).

[0226] 7. Kaplan-Meier univariate survival analysis and multivariate Cox proportional regression model analysis

[0227] Kaplan-Meier univariate survival analysis was performed on the clinicopathological factors that may affect the prognosis of HPSCC, including age, gender, tumor size, tumor location, T stage, N stage, clinical stage, tumor pathological grade, tumor diameter, presence of intravascular tumor embolus, and expression of CAFs and MLVD. The results of univariate survival analysis showed that N stage (P = 0.016), CAFs (P = 0.011), and MLVD (P = 0.009) expression affected the prognosis of hypopharyngeal squamous cell carcinoma (see Table 4).

[0228] The multiple factors affecting the prognosis of HPSCC obtained from the univariate survival analysis of the Kaplan-Meier method were incorporated into the multivariate Cox regression model to further screen the independent factors affecting the prognosis of HPSCC. The results showed that N stage (95% CI = 0.184-0.847, P = 0.017) and MLVD (95% CI = 0.296-0.986, P = 0.045) were independent risk factors for poor prognosis in HPSCC patients, and lymph node metastasis and high density of MLVD significantly increased the risk of death in patients (see Table 4).

[0229] 8. Promoting lymphangiogenesis of CAFs

[0230] In order to further clarify the relationship between HPSCC tumor-associated fibroblasts and lymphangiogenesis, and whether CAFs and NFs have different effects on lymphangiogenesis, this study conducted an in vitro three-dimensional culture tube formation experiment of lymphatic endothelial cells. The conditioned medium of CAFs and NFs was used to act on hLECs to directly observe the effects of CAFs and NFs on promoting lymphangiogenesis. Figure 5 As shown, hLECs in the control group could form a few tube-like structures, but the conditioned medium of CAF1, CAF2, CAF3, NF1, NF2, and NF3 all made hLECs form more tube-like structures.

[0231] The number of tubules formed by the conditioned medium of CAF1, CAF2, CAF3, NF1, NF2, and NF3 was more than that of the control group, and the difference was statistically significant (P<0.0001), indicating that CAFs and NFs have the effect of promoting lymphangiogenesis. Further comparison of the difference in the ability of CAFs and NFs to promote lymphangiogenesis showed that the number of tubules formed by the conditioned medium of CAF1, CAF2, and CAF3 was much greater than that of NF1, NF2, and NF3 (P<0.0001), indicating that CAFs have a stronger effect in promoting lymphangiogenesis ( Figure 6 ).

[0232] 9.ELISA detection of FGF-2 concentration in HPSCC tissues and normal adjacent tissues

[0233] In order to quantitatively measure the amount of FGF-2 in tumor tissue and adjacent tissue, the patient's tumor tissue and normal adjacent tissue were ground and the supernatant was measured to measure the FGF-2 concentration. Figure 7 As shown, the concentration in tumor tissue was higher than that in normal adjacent tissue (P=0.033).

[0234] 10.ELISA detection of CM CAFs and CM NFs The concentration of FGF-2 in

[0235] FGF-2 is expressed in cells, but it is a secretory protein that is secreted outside the cells to exert its effects. Cell immunofluorescence staining shows that the fluorescence intensity of FGF-2 in CAF1, CAF2, and CAF3 is significantly stronger than that in NF1, NF2, and NF3, but it is impossible to accurately assess the extracellular secretion of FGF-2 protein. Therefore, the conditioned medium supernatant of CAF1, NF1, CAF2, and NF2 with a cell confluence of about 80% was retained, and the protein concentration of FGF-2 in each conditioned medium supernatant was detected using an ELISA kit. The results are shown in Figures A, B, and C in Figure 8. Figure A shows that the concentration of FGF-2 in the conditioned medium supernatant of CAF1 is significantly higher than that of NF1 (P=0.005), Figure B shows that the concentration of FGF-2 in the conditioned medium supernatant of CAF2 is significantly higher than that of NF2 (P=0.024), and Figure C shows that the concentration of FGF-2 in the conditioned medium supernatant of CAF3 is significantly higher than that of NF3 (P=0.041). The above results indicate that FGF-2 can be expressed and secreted in hypopharyngeal squamous cell carcinoma CAFs cells, and its expression and secretion levels are significantly higher than those of NFs.

[0236] 12. RT-PCR detection of FGF-2 gene expression in CAFs and NFs cells

[0237] The previous ELISA experiment confirmed that the secretion of FGF-2 in CAFs was higher than that in NFs. RT-PCR was used to detect the difference in FGF-2 expression between CAFs and NFs at the mRNA expression level. Fig. 9 The results show that the mRNA level of CAFs is significantly higher than that of NFs (P=0.002), and the difference is statistically significant. It proves that the expression of FGF-2 mRNA in CAFs is higher than that in NFs.

[0238] 13. Immunofluorescence assay to detect the expression of α-SMA and FGF-2 in CAFs and NFs cells

[0239] Through RT-PCR experiments, it was found that the mRNA of FGF-2 in CAFs has a significant high expression effect. In order to understand the expression location and expression intensity of FGF-2 in CAFs, CAF1, CAF2, CAF3 and NF1, NF2, NF3 were first used for cell immunofluorescence staining to detect the expression of FGF-2. The results are shown in Fig.10 α-SMA is expressed in the cytoplasm of CAFs and NFs cells. FGF-2 is expressed in the cytoplasm and nucleus of CAFs and NFs cells. The fluorescence intensity of α-SMA in CAFs is significantly stronger than that in NFs, and the fluorescence intensity of FGF-2 in CAFs is significantly stronger than that in NFs. This indicates that the overexpression of FGF-2 in CAFs may be related to its significant lymphangiogenic effect.

[0240] 14. Western blot detection of FGF-2 expression level in CAFs and NFs cells

[0241] The expression level of FGF-2 in CAFs and NFs cells was localized and qualitatively analyzed by immunofluorescence, and then the expression level of FGF-2 in CAF1, NF1, CAF2, NF2, CAF3, and NF3 cells was quantitatively analyzed by Western blot experiments. Fig.11 The results showed that the expression level of α-SMA in CAF1, CAF2 and CAF3 cells was significantly higher than that of NF1, NF2 and NF3 proteins (P<0.0001, P2=0.0198, P3<0.0001). The expression level of FGF-2 in CAF1, CAF2 and CAF3 cells was significantly higher than that of NF1, NF2 and NF3 proteins (P1<0.0001, P2=0.0143, P3=0.0187).

[0242] Combined with the results of this section, it can be more clear that CAFs cells can highly express FGF-2, thereby promoting lymphangiogenesis.

[0243] 15. Analysis of cell activity of hLECs treated with DHA

[0244] The cell viability assay kit (CCK-8) was used to detect the effect of different concentration gradients of DHA on the activity of hLECs. hLECs seeded in a 96-well plate were given different doses of DHA and DMSO for 24 hours, and the absorbance OD value at a wavelength of 450nm was used to calculate the cell survival rate after the action of different concentration gradients of DHA on hLECs. Fig.12 As shown in Figure A, 80μM DHA has a significant inhibitory effect on hLECs cells, and the cell survival rate is significantly lower than that of hLECs cells without drug addition, with statistical difference (P<0.05). As the DHA dose increases, the inhibitory effect on hLECs cells becomes stronger and stronger, and the survival rate of hLECs cells decreases to nearly 0 when the concentration reaches 1280μM. Fig.12 Figure B is the dose-response curve obtained after nonlinear regression fitting. The horizontal axis is the DHA concentration after Log conversion. The IC50 of DHA's inhibitory effect on hLECs cells was 242.3 μM, 95% CI was 218.2-268.6 μM, and the determination coefficient R 2 The inhibitory effect of DHA on hLECs was 0.9524, and the inhibitory effect of DHA on hLECs was dependent on the drug dose. According to the IC50 results, the DHA concentration was selected as 80 μM in subsequent experiments.

[0245] 16. Changes in cell morphology after different concentrations of DHA acted on hLECs

[0246] hLECs were treated with different concentrations of DHA for 24 hours, and the cell morphology of hLECs was observed and recorded under an inverted microscope. Fig.13 As shown, in the control group (DHA = 0 μM), cells grew uniformly and densely, with a spindle shape and regular morphology, and very few dead cells; when DHA = 80 μM, cells grew uniformly and densely, with a spindle shape and regular morphology, and few dead cells. When the drug dose of the DHA intervention group was greater than 80 μM, the number of cells decreased significantly, the cells were sparse, the number of suspended dead cells in the culture medium increased, the cells adhered to the wall poorly, and the cells shrank, the cytoplasm had poor refractive index, and was turbid. When DHA = IC50, the number of cells decreased significantly; when the DHA intervention dose reached 1280 μM, the culture medium was almost entirely composed of suspended dead cells, with only a few adherent cells visible, but the cells became round and had poor refractive index. The results suggest that high concentrations of DHA inhibit the growth of hLECs cells and can change the morphology of lymphatic endothelial cells. This change is dependent on the drug dose.

[0247] 17. Cellular changes after FGF-2 combined with DHA acted on hLECs

[0248] hLECs were seeded in a six-well plate. After the cell density reached about 80%, different treatments were given. Based on references and previous experience, we set the FGF-2 concentration to 5 nM. The first group was given normal culture medium as a blank control, the second group was added with 2 ml of 5 nM FGF-2 recombinant protein in the culture medium, and the third group was treated with 5 nM FGF-2 recombinant protein + 80 μM DHA. Pictures were taken under a microscope 48 hours later. Fig.14 As shown in the figure, after adding FGF-2 recombinant protein, the number of hLECs increased significantly. In the FGF-2+DHA group, the proliferation of hLECs was significantly inhibited.

[0249] 18. Microtubule formation assay to detect the lymphangiogenesis-promoting effect of FGF-2

[0250] In order to further clarify the lymphangiogenic effect of FGF-2, an in vitro three-dimensional culture tube formation experiment of lymphatic endothelial cells was carried out using FGF-2 recombinant protein with or without the STAT3 inhibitor DHA. The effects of FGF-2 and DHA on hLECs were used to directly observe their effects on lymphangiogenesis. Fig.15 As shown, hLECs in the control group and the DHA group could form a few tube-like structures, while the addition of FGF-2 made hLECs form more tube-like structures.

[0251] The DHA group (concentration of 80 μM) had no effect on the formation of hLECs compared with the blank control group (P = 0.198). The number of tubules formed by FGF-2 was significantly more than that of the control group, and the difference was statistically significant (P = 0.0007), indicating that FGF-2 has the effect of promoting lymphangiogenesis. The number of tubes in the FGF-2 + DHA group was significantly lower than that in the FGF-2 group (P = 0.029). This indicates that DHA inhibits the lymphangiogenesis effect of FGF-2.

[0252] 19. Cell immunofluorescence detection of p-STAT3 and VEGFR-3 expression in hLECs after the action of DHA and FGF-2 recombinant proteins

[0253] hLECs were inoculated into a 24-well plate with a cell slide. Approximately 2×10 3 The cells were placed in an incubator overnight to adhere to the wall, and then replaced with DMEM complete medium containing 80 μM DHA and 5 nM FGF-2 recombinant protein. The cells were divided into blank control group, DHA group, FGF-2 group, and FGF-2+DHA group. After 24 hours of drug addition, the cells were subjected to immunofluorescence staining. The results are shown in Figure 2. Fig.16 As shown in the figure, p-STAT3 is lowly expressed in the nucleus in hLECs. After adding 80 μM DHA, the expression intensity of p-STAT3 did not change significantly. After adding FGF-2 recombinant protein alone, the expression intensity of p-STAT3 increased significantly. After adding FGF-2+DHA, the expression intensity of p-STAT3 decreased.

[0254] VEGFR-3 is expressed on the cell membrane of hLECs. When DHA was added alone, the expression of VEGFR-3 had no significant change compared with the blank control group. When FGF-2 recombinant protein was added alone, the expression intensity of VEGFR-3 increased significantly. After adding FGF-2+DHA, the expression intensity of VEGFR-3 decreased.

[0255] 20. Western blot detection of STAT3, p-STAT3, and VEGFR-3 expression in hLECs cells after the action of DHA and FGF-2 recombinant proteins

[0256] Western blot was used to detect the expression level of VEGFR-3 in lymphatic endothelial cells. Fig.17 As shown, the expression level of VEGFR-3 did not change significantly when DHA was added alone compared with the normal control group (P>0.05); the expression of VEGFR-3 increased after FGF-2 was added alone (P<0.0001); the expression level of VEGFR-3 decreased after FGF-2+DHA (P<0.0001).

[0257] The expression levels of total STAT3 and p-STAT3 were further detected, and the expression difference of p-STAT3 / STAT3 was calculated. There was no significant change in p-STAT3 / STAT3 when DHA was added alone compared with the normal control group (P=0.199); p-STAT3 / STAT3 increased compared with the normal control group after FGF-2 was added alone (P<0.0001); p-STAT3 / STAT3 decreased after FGF-2+DHA compared with FGF-2 alone (P=0.004). The above results show that FGF-2 activates the STAT3 signaling pathway in hLECs cells and increases VEGFR-3 expression. DHA, as a STAT3 inhibitor, can inhibit the activation of STAT3 and inhibit VEGFR-3 expression, thereby inhibiting lymphogenesis.

[0258] In summary, in hypopharyngeal carcinoma tissue, tumor cells, tumor-associated fibroblasts and lymphocytes interact with each other, and the mechanism by which CAFs promote lymphangiogenesis is as follows:

[0259] Normal fibroblasts are activated by tumor cells to become tumor-associated fibroblasts, which can secrete a large number of cytokines that affect tumor growth and the biological activities of other cells in the tumor stroma. Studies have found that CAFs secrete FGF-2 to act on lymphatic endothelial cells. FGF-2 binds to its receptor FGFR, and STAT3, which exists in monomers, will be phosphorylated and form dimers or polymers. These phosphorylated STAT3 complexes will migrate to the cell nucleus and bind to the promoter region of specific genes, regulating the transcription level of the following genes, affecting VEGFR-3, and thus promoting the formation of lymphatic vessels. See Fig.18 .

[0260] like Figure 1 As shown, X-tile software analyzed the optimal cutoff values ​​of α-SMA and LYVE-1 immune responses to distinguish the high / low expression groups of CAFs in HPSCC tissues (Figure A) and the high / low density groups of MLVD (Figure B). α-SMA and LYVE-1 mark CAFs and MLVD, respectively. A-1 is the optimal stage point selected by the black dots on the horizontal axis of α-SMA. A-2 is the optimal cutoff value of α-SMA displayed on the histogram of the total number of patients. A-3 is the Kaplan-Meier survival curve of high and low expression of α-SMA in the total number of cases. B-1 is the optimal stage point selected by the black dots on the horizontal axis of MLVD. B-2 is the optimal cutoff value of LYVE-1 displayed on the histogram of the total number of patients. B-3 is the Kaplan-Meier survival curve of high and low density of MLVD in the total number of cases.

[0261] like Figure 2Figure 2. Expression of α-SMA and MLVD in HPSCC tumor tissues and normal adjacent tissues. Representative fields of high and low expression of α-SMA and MLVD immunohistochemical images in HPSCC tissues, with normal tissues as the control group. Scale bar: 200 μm. HPSCC, hypopharyngeal squamous cell carcinoma; α-SMA, α-smooth muscle actin; MLVD, microlymphatic vessel density.

[0262] like Figure 3 As shown, the correlation analysis between the expression of CAFs and MVLD in HPSCC tumor tissues.

[0263] like Figure 4 As shown in the figure, Kaplan-Meier survival curves were used to analyze the relationship between CAFs, MLVD and survival rate in HPSCC patients.

[0264] A is the survival rate of the CAFs high expression density distribution group and the survival rate of the CAFs low expression density distribution group.

[0265] B is the survival rate of the MLVD high-density distribution group and the survival rate of the MLVD low-density distribution group.

[0266] like Figure 5 As shown, CAFs and NFs promote lymphangiogenesis.

[0267] like Figure 6 Shown are the statistical bar graphs of lymphangiogenesis after the action of CAFs and NFs.

[0268] like Figure 7 As shown, ELISA was used to detect the concentration of FGF-2 in HPSCC tissues and normal adjacent tissues.

[0269] like Figure 8 As shown, the concentration of FGF-2 in the conditioned medium of CAF1, NF1, CAF2, NF2, CAF3, and NF3.

[0270] like Fig. 9 As shown, real-time fluorescence quantitative PCR was used to compare the expression of FGF-2 gene in CAFs and NFs.

[0271] like Fig.10 As shown, the immunofluorescence expression and relative intensity of α-SMA and FGF-2 in CAFs and NFs cells were compared.

[0272] like Fig.11 As shown, Western blot was used to detect the protein expression levels of α-SMA and FGF-2 in CAFs and NFs cells.

[0273] like Fig.12As shown, CCK8 detected the cell activity analysis of hLECs under the action of different concentration gradients of DHA and DMSO.

[0274] like Fig.13 As shown, the cellular changes of hLECs after the action of different concentrations of DHA.

[0275] like Fig.14 As shown, the effect of FGF-2 recombinant protein with or without DHA on hLECs cells.

[0276] like Fig.15 As shown, the effect of FGF-2 recombinant protein with or without DHA on the tube formation of hLECs.

[0277] like Fig.16 As shown, the immunofluorescence expression of p-STAT3 and VEGFR-3 in human lymphatic endothelial cells hLECs after the action of FGF-2 recombinant protein and DHA.

[0278] like Fig.17 As shown, Western blot was used to detect the protein expression levels of STAT3, p-STAT3, and VEGFR-3 in lymphatic endothelial cells after DHA and FGF-2 recombinant proteins acted on the cells.

[0279] like Fig.18 As shown, in tumor tissues, tumor cells, tumor-associated fibroblasts and lymphocytes interact with each other, and CAFs promote the mechanism of lymphangiogenesis.

Claims

1. CAFs cells promote lymphangiogenesis and are used in the diagnosis and treatment of head and neck tumors.

2. The CAFs cell-mediated lymphangiogenesis-promoting method according to claim 1 is used in the diagnosis and treatment of head and neck tumors, characterized in that: CAFs are used as targets to inhibit lymphangiogenesis. Dihydroartemisinin (DHA) is used to inhibit CAFs' lymphangiogenesis and metastasis through the STAT3 pathway, thereby being used for the diagnosis and treatment of head and neck tumors.

3. The CAFs cell-mediated lymphangiogenesis-promoting method according to claim 2 is used in the diagnosis and treatment of head and neck tumors, characterized in that: CAFs promote lymphangiogenesis by secreting FGF-2.

4. The CAFs cell-mediated lymphangiogenesis-promoting method according to claim 3 is used in the diagnosis and treatment of head and neck tumors, characterized in that: FGF-2 inhibits the downstream STAT3 factor of FGF-2, thereby inhibiting the promoting effect of FGF-2 on lymphangiogenesis in hypopharyngeal cancer.

5. The CAFs cell-mediated lymphangiogenesis-promoting method according to claim 1 is used in the diagnosis and treatment of head and neck tumors, characterized in that: The regulatory role and related mechanisms of CAFs in tumor-induced lymphangiogenesis, and the use of tumor-associated fibroblasts as targets for the prevention and treatment of recurrence and metastasis of hypopharyngeal cancer.

Citation Information

Patent Citations

  • Drug composition for treating hypopharyngeal carcinoma and preparation method of drug composition

    CN110151824A